On February 8, 2024, Pharmadrug Inc. closed the transaction. Each Warrant entitles the holder to purchase one additional common share at an exercise price of CAD 0.10 at any time up to February 8, 2026. The securities issued pursuant to the Offering are subject to a hold period of four months and one day that expires on June 9, 2024.